Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Recruiting · NCT06881290 · Registry updated 2025-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2025-07-10 | NCT06881290 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese SLE Treatment And Research Group | 13 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking Union Medical College Hospital | Beijing | China | 201 |